Related Experiment Videos
Potentiation of warfarin by trimethoprim-sulfamethoxazole
Urology
|December 1, 1980
Abstract:
Potentiation of warfarin by trimethoprim-sulfamethoxazole (TMP-SMX) has been reported occasionally but not in the urologic literature. Three cases are presented in which significant bleeding developed when TMP-SMX was added for the patient already on warfarin anticoagulants. The mechanism of this interaction is uncertain but probably involves competitive protein binding by the two drugs.
Insights
Trimethoprim-sulfamethoxazole (TMP-SMX) can increase warfarin
Area of Science:
- Pharmacology
- Urology
- Internal Medicine
Background:
- Warfarin is a common anticoagulant medication.
- Trimethoprim-sulfamethoxazole (TMP-SMX) is an antibiotic.
- Drug interactions between TMP-SMX and warfarin are known but rarely documented in urologic patients.
Observation:
- Three cases of significant bleeding in patients on warfarin therapy are presented.
- Bleeding occurred after the initiation of TMP-SMX.
- These cases highlight a potential drug interaction in a urologic context.
Findings:
- TMP-SMX potentiated the anticoagulant effect of warfarin, leading to bleeding.
- The mechanism is hypothesized to involve competitive protein binding.
- This interaction was observed in patients receiving care within urology.
Implications:
- Clinicians should be aware of the potential for increased bleeding risk when prescribing TMP-SMX to patients on warfarin.
- Monitoring of anticoagulation status is crucial when these drugs are co-administered.
- Further research into the precise mechanism of this drug interaction is warranted, especially in urologic patient populations.